NCCN Guidelines® Insights - Hematopoietic Growth Factors, Version 1.2022
The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA).
Category
  • Myeloid Growth Factors
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Hematopoietic Growth Factors: Use of Thrombopoietin Receptor Agonists in Patients with Cancer
Since there is currently no FDA-approved treatment for CIT, clinicians must make decisions on the appropriate incorporation of thrombopoietin receptor agonists (TPO-RAs) into clinical practice. Increased education and awareness of the available treatment options, including TPO-RA, will help to ensure the acceptance and use of these agents in supportive oncology care for patients with CIT.
Category
  • Myeloid Growth Factors
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation